Table 4 Randomized Window-of-opportunity trials with metformin in patients with early-stage breast cancer
Author, Year [Reference] | Size | Study drug | Comparator | Duration of Treatment (days) | Findings |
|---|---|---|---|---|---|
Hadad (2011)84 | 47 | Metformin 500 mg/day (first week) → 1000 mg twice per day (second week) | No treatment | 14 | Reduction of Ki-67 levels on metformin (p = 0.027) |
*Bonanni (2012)85 | 200 | Metformin 850 mg days 1–3 → 850 mg twice per day | Placebo | 28 | Metformin did not significantly reduce Ki-67 overall but only in insulin resistant women |
*DeCensi (2015)86 | 200 | Metformin 850 mg days 1–3 → 850 mg twice per day | Placebo | 28 | Metformin reduced Ki-67 in HER2 + DCIS |
